0001209191-20-048318.txt : 20200825
0001209191-20-048318.hdr.sgml : 20200825
20200825214516
ACCESSION NUMBER: 0001209191-20-048318
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200821
FILED AS OF DATE: 20200825
DATE AS OF CHANGE: 20200825
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Funtleyder Leslie D.
CENTRAL INDEX KEY: 0001775394
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38898
FILM NUMBER: 201134021
MAIL ADDRESS:
STREET 1: C/O APPLIED THERAPEUTICS, INC.
STREET 2: 340 MADISON AVENUE, 19TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10173
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Applied Therapeutics Inc.
CENTRAL INDEX KEY: 0001697532
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 545 5TH AVENUE, SUITE 1400
CITY: NEW YORK
STATE: NY
ZIP: 10017
BUSINESS PHONE: 212-220-9319
MAIL ADDRESS:
STREET 1: 545 5TH AVENUE, SUITE 1400
CITY: NEW YORK
STATE: NY
ZIP: 10017
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-08-21
0
0001697532
Applied Therapeutics Inc.
APLT
0001775394
Funtleyder Leslie D.
C/O APPLIED THERAPEUTICS, INC.
545 FIFTH AVENUE, SUITE 1400
NEW YORK
NY
10017
1
0
0
0
Common Stock
2020-08-21
4
M
0
20000
4.70
D
37148
D
Common Stock
2020-08-24
4
S
0
13539
23.42
D
23609
D
Common Stock
2020-08-24
4
S
0
6461
24.18
A
17148
D
Stock Option (Right to Buy)
4.70
2020-08-21
4
M
0
20000
0.00
D
2029-03-06
Common Stock
20000
70502
D
Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised pursuant to the reporting person's written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
Sales made pursuant to the reporting person's written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
Weighted average price. These shares were sold in multiple transactions at prices ranging from $22.9400 to $23.8600 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Weighted average price. These shares were sold in multiple transactions at prices ranging from $23.9700 to $24.4100 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
These options became fully vested on May 28, 2019.
/s/ Shoshana Shendelman as attorney-in-fact
2020-08-25